E. De-plaen, C. Lurquin, A. Van-pel, B. Mariame, J. P. Szikora et al., Immunogenic (tum ? ) variants of mouse tumor P815: cloning of the gene of tum ? antigen P91A and identification of the tum ? mutation, Proc. Natl. Acad. Sci. USA, vol.85, p.2274, 1988.

P. Dubey, R. C. Hendrickson, S. C. Meredith, C. T. Siegel, J. Shabanowitz et al., The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68, J. Exp. Med, vol.185, p.695, 1997.

R. T. Prehn and J. M. Main, Immunity to methylcholanthrene-induced sarcomas, J. Natl. Cancer Inst, vol.18, p.769, 1998.

T. Wolfel, M. Hauer, J. Schneider, M. Serrano, C. Wolfel et al., A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma, Science, vol.269, p.1281, 1995.

J. F. Baurain, D. Colau, N. Van-baren, C. Landry, V. Martelange et al., High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene, J. Immunol, vol.164, p.6057, 2000.

S. A. Rosenberg, Immunotherapy and gene therapy of cancer, Cancer Res, vol.51, p.5074, 1991.

P. D. Greenberg, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv. Immunol, vol.49, p.281, 1991.

J. L. Bos, ras oncogenes in human cancer: a review, Cancer Res, vol.49, p.4682, 1989.

S. Weijzen, M. P. Velders, and W. M. Kast, Modulation of the immune response and tumor growth by activated Ras, Leukemia, vol.13, p.502, 1999.

A. Van-elsas, H. W. Nijman, C. E. Van-der-minne, J. S. Mourer, W. M. Kast et al., Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 ras peptide presented by HLA-A*0201, Int. J. Cancer, vol.61, p.389, 1995.

M. K. Gjertsen, J. Bjorheim, I. Saeterdal, J. Myklebust, and G. Gaudernack, Cytotoxic CD4 ? and CD8 ? T lymphocytes, generated by mutant p21 ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation, Int. J. Cancer, vol.72, p.784, 1997.

S. I. Abrams, S. N. Khleif, E. S. Bergmann-leitner, J. A. Kantor, Y. Chung et al., Generation of stable CD4 ? and CD8 ? T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations, Cell. Immunol, vol.182, p.137, 1997.

L. E. Bergmann, J. A. Kantor, W. L. Shupert, J. Schlom, and S. I. Abrams, Identification of a human CD8 ? T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele, Cell. Immunol, vol.187, p.103, 1998.

Y. Hasegawa, S. Takeda, S. Ichii, K. Koizumi, M. Maruyama et al., Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allelespecific amplification (MASA), Oncogene, vol.10, p.1441, 1995.

R. M. Ferrie, M. J. Schwarz, N. H. Robertson, S. Vaudin, M. Super et al., Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene, Am. J. Hum. Genet, vol.51, p.251, 1992.

S. Bezieau, M. C. Devilder, H. Avet-loiseau, M. P. Mellerin, D. Puthier et al., High incidence of N and K-ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis, Hum. Mutat, vol.18, p.281, 2001.
URL : https://hal.archives-ouvertes.fr/hal-01595830

F. Sanger, S. Nicklen, and A. R. Coulson, DNA sequencing with chainterminating inhibitors, Proc. Natl. Acad. Sci, vol.74, p.5463, 1977.

A. Kelly, S. H. Powis, L. A. Kerr, I. Mockridge, T. Elliott et al., Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex, Nature, vol.355, p.641, 1992.

B. Seed and A. Aruffo, Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure, Proc. Natl. Acad. Sci, vol.84, p.3365, 1987.

V. Brichard, A. Van-pel, T. Wolfel, C. Wolfel, E. De-plaen et al., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med, vol.178, p.489, 1993.

E. De-plaen, C. Lurquin, B. Lethe, P. Van-der-bruggen, V. Brichard et al., Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes, Methods, vol.12, p.125, 1997.

N. Labarriere, M. C. Pandolfino, D. Raingeard, S. L. Guiner, E. Diez et al., Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes, Int. J. Cancer, vol.78, p.209, 1998.

M. K. Gjertsen, A. Bakka, J. Breivik, I. Saeterdal, B. G. Solheim et al., Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation, Lancet, vol.346, p.1399, 1995.

B. Fossum, T. R. Gedde, J. Dahl, J. A. Breivik, A. Eriksen et al., p21 ras -peptide-specific T-cell responses in a patient with colorectal cancer: CD4 ? and CD8 ? T cells recognize a peptide corresponding to a common mutation (13Gly3 Asp), Int. J. Cancer, vol.56, p.40, 1994.

B. Fossum, A. C. Olsen, E. Thorsby, and G. Gaudernack, CD8 ? T cells from a patient with colon carcinoma, specific for a mutant p21 ras -derived peptide (Gly133 Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation, Cancer Immunol. Immunother, vol.40, p.165, 1995.

C. Gouttefangeas, C. Demeur, F. Connan, N. Balayn, J. Choppin et al., Differential binding to frequent HLA-A alleles of p21 ras derived peptides bearing oncogenic substitutions at position 12 or 13, Hum. Immunol, vol.55, p.117, 1997.

D. Bar-sagi, A Ras by any other name, Mol. Cell. Biol, vol.21, p.1441, 2001.

T. Papp, H. Pemsel, R. Zimmermann, R. Bastrop, D. G. Weiss et al., Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi, J. Med. Genet, vol.36, p.610, 1999.

C. T. Esapa, S. J. Johnson, P. Kendall-taylor, T. W. Lennard, and P. E. Harris, Prevalence of ras mutations in thyroid neoplasia, vol.50, p.529, 1999.

N. P. Restifo and S. A. Rosenberg, Developing recombinant and synthetic vaccines for the treatment of melanoma, Curr. Opin. Oncol, vol.11, p.50, 1999.

E. A. Walter, P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe et al., Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor, N. Engl. J. Med, vol.333, p.1038, 1995.

C. T. Siegel, K. Schreiber, S. C. Meredith, G. B. Beck-engeser, D. W. Lancki et al., Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein, J. Exp. Med, vol.191, 1945.

C. J. Melief, S. Schoenberger, R. Toes, and R. Offringa, Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells, Haematologica, vol.84, p.26, 1999.

Y. Noguchi, Y. T. Chen, and L. J. Old, A mouse mutant p53 product recognized by CD4 ? and CD8 ? T cells, Proc. Natl. Acad. Sci. USA, vol.91, p.3171, 1994.

O. Mandelboim, E. Vadai, M. Fridkin, A. Katz-hillel, M. Feldman et al., Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides, Nat. Med, vol.1, p.1179, 1995.

S. Bertholet, R. Iggo, and G. Corradin, Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides, Eur. J. Immunol, vol.27, p.798, 1997.

H. Ikeda, N. Ohta, K. Furukawa, H. Miyazaki, L. Wang et al., Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma, Proc. Natl. Acad. Sci. USA, vol.94, p.6375, 1997.

H. L. Hanson, D. L. Donermeyer, H. Ikeda, J. M. White, V. Shankaran et al., Eradication of established tumors by CD8 ? T cell adoptive immunotherapy, Immnunity, vol.13, p.265, 2000.